<DOC>
	<DOCNO>NCT00619060</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention use certain drug keep cancer forming . The use topical myristyl nicotinate cream may stop skin cancer forming . PURPOSE : This randomized phase I trial study side effect best way give topical myristyl nicotinate cream skin healthy volunteer .</brief_summary>
	<brief_title>Topical Myristyl Nicotinate Cream Skin Healthy Volunteers</brief_title>
	<detailed_description>OBJECTIVES : - To determine topical myristyl nicotinate ( MN ) safe , tolerable treatment healthy volunteer . - To determine topically administer MN cream associate significant local systemic toxicity normal human subject one-month period . OUTLINE : Participants randomize 1 2 treatment arm serve control . - Arm I : Participants apply topical myristyl nicotinate one forearm topical placebo forearm daily 4 week . - Arm II : Participants receive treatment arm I opposite forearm . All participant undergo blood collection chemistry analysis ( SMA-20 CBC ) baseline 2 4 week .</detailed_description>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Subjects 18 year age old normal skin Have use topical medication skin upper extremity , except emollient sunscreen , least 30 day prior study entry Agree limit sun exposure much possible wear protective clothing forearm place use sunscreen moisturizers Ability understand willingness sign inform consent initiation therapy nature study explain Females must surgically sterile hysterectomy post menopausal Subjects sign inflammation irritation skin forearm Subjects prior history actinic keratosis skin cancer forearm Females child bear potential Subjects concurrent therapy ( e.g. , retinoids , fluorouracil ) forearm may interfere clinical evaluation Subjects take oral supplemental niacin , form multivitamin exceed 40 mg/day No known immunosuppression virtue medication disease , include AIDS patient , subject take oral prednisone , subject immunosuppressants/immunomodulators ( cyclosporine , chemotherapeutic agent , biologic therapy ) , determine examine investigator/coinvestigator Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Subjects invasive cancer within past 5 year Skin condition felt study physician contraindicate enrollment include , limited , psoriasis atopic dermatitis within propose treatment area Less 30 day since prior concurrent plan participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>skin cancer</keyword>
	<keyword>healthy , evidence disease</keyword>
</DOC>